Research is being conducted on proteolysis-targeting chimeras, or PROTACs, in the context of leukemia, with various studies and reviews exploring their potential applications, challenges, and future directions. The technology is being investigated for its ability to target and degrade specific proteins, with potential implications for the treatment of hematological malignancies. The current status and future prospects of PROTACs in targeted therapy are being discussed in the scientific community.